Literature DB >> 11274974

Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells.

S N Wu1, H F Li, H T Chiang.   

Abstract

The effects of vinpocetine, an inhibitor of cyclic GMP phosphodiesterase, on ionic currents were examined in rat pituitary GH3 lactotrophs with the aid of the patch-clamp technique. In GH3 cells bathed in normal Tyrode's solution, vinpocetine (10 microM) reversibly increased the amplitude of Ca2+-activated K+ current (I(K)Ca) with an EC50 value of 4 microM. When the recording pipettes were filled with 10 mM EGTA, vinpocetine also stimulated I(K)Ca. In the cell-attached configuration, application of vinpocetine to the bath increased the activity of large-conductance Ca2+-activated K+ (BK(Ca)) channels. In excised membrane patches, application of vinpocetine (10 microM) to the bath did not change the single-channel conductance of BK(Ca) channels; however, it did increase channel activity. In the inside-out configuration, neither 8-bromo cyclic GMP nor YC-1 applied intracellularly affected BK(Ca) channel activity. The vinpocetine-induced change in the kinetic behavior of BK(Ca) channels was due to an increase in mean open time and a decrease in mean closed time. Vinpocetine (10 microM) caused a leftward shift in the midpoint for the voltage-dependent opening. Under the current-clamp mode, vinpocetine (10 microM) decreased the firing rate of spontaneous action potentials induced by thyrotropin-releasing hormone (10 microM) in GH3 cells. In pheochromocytoma PC12 cells, vinpocetine (10 microM) applied intracellularly also enhanced the activity of BK(Ca) channels without altering single-channel conductance. Thus, the present study suggests that vinpocetine-mediated stimulation of I(K)Ca may result from the direct activation of BK(Ca) channels and indirectly from elevated cytosolic Ca2+.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274974     DOI: 10.1016/s0006-2952(01)00553-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries.

Authors:  Makhala Michell Khammy; Thomas Dalsgaard; Peter Hjørringgaard Larsen; Claus Tornby Christoffersen; Dorte Clausen; Lars Kyhn Rasmussen; Lasse Folkersen; Morten Grunnet; Jan Kehler; Christian Aalkjaer; Jacob Nielsen
Journal:  Br J Pharmacol       Date:  2017-10-15       Impact factor: 8.739

Review 3.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

Review 4.  Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.

Authors:  Arun Samidurai; Lei Xi; Anindita Das; Audra N Iness; Navin G Vigneshwar; Pin-Lan Li; Dinender K Singla; Sakthivel Muniyan; Surinder K Batra; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2021-04-22       Impact factor: 13.400

5.  Memory in astrocytes: a hypothesis.

Authors:  Robert M Caudle
Journal:  Theor Biol Med Model       Date:  2006-01-18       Impact factor: 2.432

6.  Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord.

Authors:  Kenji W Ruiz-Miyazawa; Ana C Zarpelon; Felipe A Pinho-Ribeiro; Gabriela F Pavão-de-Souza; Rubia Casagrande; Waldiceu A Verri
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

7.  The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target.

Authors:  Stefan Kunz; Vreni Balmer; Geert Jan Sterk; Michael P Pollastri; Rob Leurs; Norbert Müller; Andrew Hemphill; Cornelia Spycher
Journal:  PLoS Negl Trop Dis       Date:  2017-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.